Evidence map›Paper›PMID 38692418›Full record

ArticleVascular pharmacology2024

Effects of Empagliflozin on Vascular and Skeletal Mineralization in Hyperlipidemic Mice.

Sophia Kalanski, Stuti Pradhan, Andy Hon, Yuxuan Xia, Nora Safvati, Juan Carlos Rivera, Mimi Lu, Linda L Demer, Yin Tintut

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sophia KalanskiDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Stuti PradhanDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Andy HonDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Yuxuan XiaDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Nora SafvatiDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Juan Carlos RiveraDivision of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R. Drew University, Los Angeles, California, USA.
Mimi LuDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Linda L DemerDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, California, USA; Department of Physiology, University of California, Los Angeles, Los Angeles, California, USA.
Yin TintutDivision of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA; Department of Physiology, University of California, Los Angeles, Los Angeles, California, USA; Department of Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, USA. Electronic address: ytintut@mednet.ucla.edu.
University of California, Los Angeles · USCharles R. Drew University of Medicine and Science · US

Funding

Role of intermittent activation of parathyroid hormone receptor in exercise-induced vascular calcificationR01HL151391 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2021 to 2024
$2.2M
Serotonin receptor contribution to inflammation-induced calcific aortic valve diseaseR01HL137647 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEMER, LINDA L., TINTUT, YIN · 2019 to 2022
$1.6M
NHLBI NIH HHS R01 HL137647NHLBI NIH HHS R01 HL151391NIH NHLBI HL 151391
6 · The paper itself

Abstract

Cardiovascular disease and osteoporosis, major causes of morbidity and mortality, are associated with hyperlipidemia. Recent studies show that empagliflozin (EMPA), an inhibitor of sodium-glucose cotransporter-2 (SGLT2), improves cardiovascular health. In preclinical animal studies, EMPA mitigates vascular calcification in the males but its effects in the females are not known. Thus, we used female mice to test the effects of EMPA on calcification in the artery wall, cardiac function, and skeletal bone. By serial in vivo microCT imaging, we followed the progression of aortic calcification and bone mineral density in young and older female Apoe

Indexed as

Benzhydryl CompoundsBone DensityDisease Models, AnimalGlucosidesHyperlipidemiasMice, Knockout, ApoESodium-Glucose Transporter 2 InhibitorsVascular CalcificationX-Ray MicrotomographyAge FactorsAnimalsAortaAortic DiseasesCells, CulturedDiet, High-FatFemaleBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsEmpagliflozinHyperlipidemiaSGLT2

Identifiers

PMID38692418
PMCPMC12077419
OpenAlexW4396495530

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.